文献速递骨软组织肉瘤与黑色素瘤

定义转移性黑色素瘤抗PD-1抗体单药或联合伊匹木单抗治疗反应与生存的临床模型

Clinical Models to Define Response and Survival With Anti-PD-1 Antibodies Alone or Combined With Ipilimumab in Metastatic Melanoma.
PubMed 文献 · J Clin Oncol · 2022-02-10

PURPOSE: Currently, there are no robust biomarkers that predict immunotherapy outcomes in metastatic melanoma. We sought to build multivariable predictive models for response and survival to anti-programmed cell death protein 1 (anti-PD-1) monotherapy or in combination with antic…

要点

  • 预测客观缓解率的模型含体能状态、肝/肺转移、乳酸脱氢酶、中性粒细胞淋巴细胞比值、治疗类型和线数,AUC=0.71。
  • 预测无进展生存和总生存的模型含上述变量(除肺转移)及脑转移和血红蛋白,AUC分别为0.68和0.77。
  • 已基于临床模型开发列线图计算器,用于预测抗PD-1±伊匹木单抗治疗患者的结局。

核心结论

  • 新开发的组合常规基线临床因素可预测转移性黑色素瘤患者接受免疫治疗的反应和生存结局,可能作为临床决策的有价值工具。

研究设计与样本

  • 发现队列N=633,验证队列1 N=419,验证队列2 N=592。
  • 采用惩罚回归方法(最小绝对收缩和选择算子)筛选预测因子,并建立列线图。

主要发现

  • 预测客观缓解率的最终模型AUC=0.71,包含东部肿瘤协作组体能状态、肝转移有无、肺转移有无、血清乳酸脱氢酶、血中性粒细胞淋巴细胞比值、治疗(单药/联合)和既往治疗线数。
  • 预测无进展生存的最终模型AUC=0.68,包含客观缓解率模型中的变量(除肺转移有无),并包括脑转移有无和血红蛋白。
  • 预测总生存的最终模型AUC=0.77,包含客观缓解率模型中的变量(除肺转移有无),并包括脑转移有无和血红蛋白。

关键数值与推荐

  • 客观缓解率预测模型AUC=0.71。
  • 无进展生存预测模型AUC=0.68。
  • 总生存预测模型AUC=0.77。

临床怎么用

  • 作者认为新开发的常规基线临床因素组合模型可预测免疫治疗的反应和生存结局,可能作为临床决策的有价值工具。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Currently, there are no robust biomarkers that predict immunotherapy outcomes in metastatic melanoma. We sought to build multivariable predictive models for response and survival to anti-programmed cell death protein 1 (anti-PD-1) monotherapy or in combination with anticytotoxic T-cell lymphocyte-4 (ipilimumab [IPI]; anti-PD-1 ± IPI) by including routine clinical data available at the point of treatment initiation. METHODS: One thousand six hundred forty-four patients with metastatic melanoma treated with anti-PD-1 ± IPI at 16 centers from Australia, the United States, and Europe were included. Demographics, disease characteristics, and baseline blood parameters were analyzed. The end points of this study were objective response rate (ORR), progression-free survival (PFS), and overall survival (OS). The final predictive models for ORR, PFS, and OS were determined through penalized regression methodology (least absolute shrinkage and selection operator method) to select the most significant predictors for all three outcomes (discovery cohort, N = 633). Each model was validated internally and externally in two independent cohorts (validation-1 [N = 419] and validation-2 [N = 592]) and nomograms were created. RESULTS: The final model for predicting ORR (area under the curve [AUC] = 0.71) in immunotherapy-treated patients included the following clinical parameters: Eastern Cooperative Oncology Group Performance Status, presence/absence of liver and lung metastases, serum lactate dehydrogenase, blood neutrophil-lymphocyte ratio, therapy (monotherapy/combination), and line of treatment. The final predictive models for PFS (AUC = 0.68) and OS (AUC = 0.77) included the same variables as those in the ORR model (except for presence/absence of lung metastases), and included presence/absence of brain metastases and blood hemoglobin. Nomogram calculators were developed from the clinical models to predict outcomes for patients with metastatic melanoma treated with anti-PD-1 ± IPI. CONCLUSION: Newly developed combinations of routinely collected baseline clinical factors predict the response and survival outcomes of patients with metastatic melanoma treated with immunotherapy and may serve as valuable tools for clinical decision making.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Pires da Silva I, Ahmed T, McQuade JL, et al. Clinical Models to Define Response and Survival With Anti-PD-1 Antibodies Alone or Combined With Ipilimumab in Metastatic Melanoma. J Clin Oncol. 2022. PMID: 35143285. doi:10.1200/JCO.21.01701

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。